In yesterday’s Wall Street session, Seelos Therapeutics Inc (NASDAQ:SEEL) shares traded at $0.17, up 5.34% from the previous session.
2 analysts cover Seelos Therapeutics Inc (NASDAQ:SEEL), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $4.00, we find $4.00. Given the previous closing price of $0.16, this indicates a potential upside of 2400.0 percent. SEEL stock price is now -59.78% away from the 50-day moving average and -79.16% away from the 200-day moving average. The market capitalization of the company currently stands at $25.94M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 1 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $4.00 as their price target over the next twelve months.
With the price target enhanced from $2.50 to $8, ROTH Capital Upgraded its rating from Neutral to Buy for Seelos Therapeutics Inc (NASDAQ: SEEL).
A total of 2.17% of the company’s stock is owned by insiders.
During the past 12 months, Seelos Therapeutics Inc has had a low of $0.15 and a high of $1.66. The fifty day moving average price for SEEL is $0.4320 and a two-hundred day moving average price translates $0.8329 for the stock.
The latest earnings results from Seelos Therapeutics Inc (NASDAQ: SEEL) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.22, missing analysts’ expectations of -$0.09 by -0.13. This compares to -$0.20 EPS in the same period last year. The net profit margin was -7096.85% and return on equity was -584.20% for SEEL. For the current quarter, analysts expect SEEL to generate $100k in revenue.
Seelos Therapeutics Inc(SEEL) Company Profile
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson’s disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
